New hope for rare tumor patients: chemo delivered directly to desmoid growths
NCT ID NCT06268457
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with symptomatic desmoid tumors that are growing and cannot be treated with surgery or freezing. Researchers are testing a procedure that delivers chemotherapy (doxorubicin) directly into the tumor through a small tube in an artery, aiming to shrink the tumor and reduce pain. The study will follow 20 participants over time to see if this approach is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients affected by desmoid fibromatoses eligible to be treated with chemoembolization with Doxorubicin
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * FIbromatosis demsoid symptomatic and in active phase (documented growth at last follow-ups) * Patients who are not candidates for surgery or cryoablation Exclusion Criteria: * Patients with life expectancy \<3 months or severely impaired status functional status (ASA 4) * Patients with fibromatosis not in active phase, documented clinically and by investigations imaging (MRI, CT) * Patients with coagulation deficiency or plateletopenic disease * Patients with documented active infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Desmoid are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Istituto Ortopedico Rizzoli
RECRUITINGBologna, Emilia-Romagna, 40136, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging method may spot tumor growth earlier after freezing treatment
- New hope for rare tumor patients: AL102 drug trial launches
- Can a Stress-Management program help young cancer patients cope?
- New Tamoxifen-Like drug tested for stubborn hormone cancers
- New drug FOG-001 takes on Hard-to-Treat cancers